Hermes Biosciences

Executive Summary

Hermes Biosciences is a private biotechnology company based in South San Francisco, specializing in the development of benchtop, hands-off extracellular vesicle (EV) isolation systems. The company’s proprietary technology enables direct processing of bodily fluids and cell culture media to purify exosomes quickly, efficiently, and with high reproducibility. This addresses a critical bottleneck in exosome research, where consistent isolation is essential for understanding exosome function in oncology, degenerative diseases, and regenerative medicine. By providing a standardized and automated solution, Hermes aims to accelerate both basic research and clinical translation of exosome-based diagnostics and therapeutics. The market for exosome isolation tools is growing rapidly, driven by increasing interest in liquid biopsies and cell-free therapies. Hermes’ platform differentiates through its simplicity and versatility, potentially capturing significant share in academic and pharmaceutical research labs. The company’s long-standing presence since 2003 suggests deep expertise and a validated product pipeline. Key catalysts include the launch of an upgraded system targeting clinical applications, a strategic partnership with a major diagnostics firm, and expansion into the emerging field of exosome-based drug delivery. With a robust technology foundation and clear market need, Hermes is well-positioned for growth.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation Exosome Isolation System75% success
• Q4 2026Partnership with Major Diagnostics Company60% success
• H1 2027Expansion into Drug Delivery Collaborations50% success